ATX code: M02AC
INSTRUCTIONS FOR USE
KUPIN GEL
QUPEN GEL
Trade name of the drug: Kupin gel
Active ingredients (INN): diclofenac, methyl salicylate, menthol, linseed oil
Dosage form: gel for external use.
Composition
Each tube contains:
active ingredients: flaxseed oil (α-linseed acid dominates in the composition) 3.00% w/v, diclofenac diethylamine 1.16% w/v (corresponding to the content of diclofenac sodium 1.00% w/v), methyl salicylate BF 10.00 % w/v, menthol 5.00% w/v.
excipients: benzyl alcohol, carbomer 940, triethanolamine, propylene glycol, polyoxyl 40 hydrogenated castor oil (Acryzol K-140), isopropyl alcohol, methylhydroxybenzoate, propylhydroxybenzoate, purified liquid paraffin, white soft paraffin, tosalangan suv.
Description : homogeneous gel of white or almost white color with a characteristic odor.
Pharmacotherapeutic group: topical anti-inflammatory agent.
Code ATH : M02AC
Pharmacological properties
Kupin gel contains diclofenac sodium, a non-steroidal substance that has a pronounced anti-inflammatory, analgesic and antipyretic effect.
The main mechanism of action of diclofenac, established under experimental conditions, is considered to be inhibition of prostaglandin biosynthesis. Prostaglandins play an important role in the genesis of inflammation, pain and fever. In rheumatic diseases, the anti-inflammatory and analgesic properties of diclofenac provide a clinical effect, characterized by a significant reduction in the severity of symptoms and complaints such as pain at rest and with movement, morning stiffness and swelling of the joints, as well as improved function. In vitro, diclofenac sodium, in concentrations equivalent to those achieved in the treatment of patients, does not inhibit the biosynthesis of proteoglycans in cartilage tissue.
In case of post-traumatic and postoperative inflammatory phenomena, diclofenac quickly relieves pain (both spontaneous and occurring during movement), reduces inflammatory swelling and swelling of the postoperative wound.
Indications for use
Kupin Gel is a topical analgesic and anti-inflammatory gel indicated for pain, swelling and inflammation associated with musculoskeletal injuries: sprains, tendinitis, bursitis, arm, neck, shoulder pain, sciatica, joint stiffness, back pain and lumbago. .
Directions for use and doses
Kupin gel is applied 3-4 times a day to the affected areas, massaging until the medicinal mass disappears.
Side effects
Side effects such as rash, itching and redness are possible. Side effects usually disappear after stopping use of the drug. If symptoms persist, please consult your doctor.
Contraindications
Kupin gel is contraindicated in patients with hypersensitivity to diclofenac, aspirin, other non-steroidal anti-inflammatory drugs and other ingredients of the drug.
Drug interactions
Since the systemic absorption of diclofenac due to topical administration of the drug is very low, the likelihood of interactions is very low. The drug should be used with caution in combination with other NSAIDs. Diclofenac may enhance the effect of drugs that cause photosensitivity.
special instructions
The likelihood of developing systemic side effects with topical use of diclofenac compared to its oral administration is low, but increases when Kupin gel is applied to relatively large surfaces of the skin for a long time.
Kupin gel is recommended to be applied only to intact areas of the skin, avoiding contact with damaged, inflamed or infected areas and open wounds. It should not come into contact with the eyes or other mucous membranes. The drug cannot be taken orally.
If any skin rash appears, treatment with the drug should be discontinued. Kupin gel should not be used under a waterproof occlusive dressing. In the case of a sprain, a bandage may be applied to the affected area.
Kupin gel is not used on open wounds.
Use during pregnancy and lactation
During pregnancy and lactation, consult your doctor before using the drug. Since clinical experience with the use of the drug in pregnant or breastfeeding women is limited, it is not recommended for use during pregnancy and breastfeeding. This especially applies to the third trimester of pregnancy due to the likely effect on the contractility of the myometrium and the possibility of developing weakness of labor and/or premature closure of the ductus arteriosus.
Animal studies have not revealed evidence of a negative effect on pregnancy, fetal development, childbirth or postnatal development.
If it is absolutely necessary to use the drug during breastfeeding, when the expected benefit outweighs the potential risk, the drug should not be applied to the chest area or to a large surface of the skin, and should not be used for a long time.
The drug should not be used after the expiration date and should be stored out of the reach of children.
